What does BELDIMED do?

BELDIMED is registered with the CBE as active in: Groothandel in farmaceutische producten. Public Limited, started on 8 February 1994, 1 establishment.

What is the address of BELDIMED?

The registered office of BELDIMED is located at Rue Zénobe Gramme 39, 4821 Dison.

Is BELDIMED still active?

Yes. According to the CBE (29 October 2026) BELDIMED is active, legal situation “Normale toestand”, started on 8 February 1994.

Is BELDIMED registered on Peppol?

Yes, BELDIMED is registered on the Peppol network with ID 0208:0451903697.

What is the enterprise number of BELDIMED?

The enterprise number of BELDIMED is BE0451903697.

When was BELDIMED founded?

BELDIMED was founded on 8 February 1994.

Who are the directors of BELDIMED?

According to the 2025 annual accounts, the directors of BELDIMED are: Eagle Finance.

Is BELDIMED a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 8 February 1994; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did BELDIMED make in 2025?

BELDIMED posted a profit after taxes of € 38,202 in financial year 2025.

What is the revenue of BELDIMED?

As a small company, BELDIMED is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 789,471.

How much does an employee at BELDIMED earn?

The average wage cost per full-time employee at BELDIMED was € 68,600 in 2025: staff costs of € 596,968 for 8.7 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does BELDIMED have?

According to the 2025 annual accounts, BELDIMED has 8.7 full-time equivalents (FTE).

Does BELDIMED have a website?

Yes, BELDIMED has a website at beldimed.com.

BELDIMED (Public Limited) - Dison - BE0451903697

Dossier BELDIMED, printed on 29 October 2026 from databakkes.be/en/0451903697/beldimed. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

BELDIMED from Dison, company number BE0451903697, closed financial year 2025 with a result of € 38,202 after tax. For that financial year BELDIMED recorded a gross margin of € 789,471 and equity of € 681,049. Compared with financial year 2024, the result moved from € 157,019 to € 38,202. The company is profitable. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 17, 2026.

What it is worth Healthy

€ 681,049

▼ 14% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 38,202

▼ 76% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 345,804

▼ 38% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 150,000 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Full-time equivalents

8.7

▲ 0.9 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 596,968

▲ 1% vs 2024

€ 68,600 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 6,459

▼ 33% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 838,083

▼ 33% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 105,557

▼ 7% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 682,313 Gross margin 2022: € 682,313 First fiscal year in the series	€ 677,159 Gross margin 2023: € 677,159 ▼ 1% vs 2022 (€ 682,313) Unfavourable step	€ 1,092,907 Gross margin 2024: € 1,092,907 ▲ 61% vs 2023 (€ 677,159) Favourable step	€ 789,471 Gross margin 2025: € 789,471 ▼ 28% vs 2024 (€ 1,092,907) Unfavourable step	▼ 28%
Profit after taxes	€ 72,511 Profit after taxes 2022: € 72,511 First fiscal year in the series	€ -10,455 Profit after taxes 2023: € -10,455 ▼ € 82,967 vs 2022 (€ 72,511) Unfavourable step	€ 157,019 Profit after taxes 2024: € 157,019 ▲ € 167,474 vs 2023 (€ -10,455) Favourable step	€ 38,202 Profit after taxes 2025: € 38,202 ▼ 76% vs 2024 (€ 157,019) Unfavourable step	▼ 76%
Equity	€ 996,284 Equity 2022: € 996,284 First fiscal year in the series	€ 885,829 Equity 2023: € 885,829 ▼ 11% vs 2022 (€ 996,284) Unfavourable step	€ 792,847 Equity 2024: € 792,847 ▼ 10% vs 2023 (€ 885,829) Unfavourable step	€ 681,049 Equity 2025: € 681,049 ▼ 14% vs 2024 (€ 792,847) Unfavourable step	▼ 14%
Total debts	€ 1,358,876 Total debts 2022: € 1,358,876 First fiscal year in the series	€ 1,434,371 Total debts 2023: € 1,434,371 ▲ 6% vs 2022 (€ 1,358,876) Unfavourable step	€ 1,613,066 Total debts 2024: € 1,613,066 ▲ 12% vs 2023 (€ 1,434,371) Unfavourable step	€ 1,481,837 Total debts 2025: € 1,481,837 ▼ 8% vs 2024 (€ 1,613,066) Favourable step	▼ 8%
Cash	€ 673,326 Cash 2022: € 673,326 First fiscal year in the series	€ 235,370 Cash 2023: € 235,370 ▼ 65% vs 2022 (€ 673,326) Unfavourable step	€ 562,206 Cash 2024: € 562,206 ▲ 139% vs 2023 (€ 235,370) Favourable step	€ 345,804 Cash 2025: € 345,804 ▼ 38% vs 2024 (€ 562,206) Unfavourable step	▼ 38%
Retained profit	€ 934,311 Retained profit 2022: € 934,311 First fiscal year in the series	€ 823,855 Retained profit 2023: € 823,855 ▼ 12% vs 2022 (€ 934,311) Unfavourable step	€ 730,874 Retained profit 2024: € 730,874 ▼ 11% vs 2023 (€ 823,855) Unfavourable step	€ 619,049 Retained profit 2025: € 619,049 ▼ 15% vs 2024 (€ 730,874) Unfavourable step	▼ 15%
Dividend	€ 300,000 Dividend 2022: € 300,000 First fiscal year in the series	€ 100,000 Dividend 2023: € 100,000 ▼ 67% vs 2022 (€ 300,000) Unchanged	€ 250,000 Dividend 2024: € 250,000 ▲ 150% vs 2023 (€ 100,000) Unchanged	€ 150,000 Dividend 2025: € 150,000 ▼ 40% vs 2024 (€ 250,000) Unchanged	▼ 40%
Balance sheet total	€ 2,355,160 Balance sheet total 2022: € 2,355,160 First fiscal year in the series	€ 2,320,200 Balance sheet total 2023: € 2,320,200 ▼ 1% vs 2022 (€ 2,355,160) Unchanged	€ 2,405,914 Balance sheet total 2024: € 2,405,914 ▲ 4% vs 2023 (€ 2,320,200) Unchanged	€ 2,162,886 Balance sheet total 2025: € 2,162,886 ▼ 10% vs 2024 (€ 2,405,914) Unchanged	▼ 10%
Employees (FTE)	7.7 Employees (FTE) 2022: 7.7 First fiscal year in the series	7.1 Employees (FTE) 2023: 7.1 ▼ 0.6 vs 2022 (7.7) Unchanged	7.8 Employees (FTE) 2024: 7.8 ▲ 0.7 vs 2023 (7.1) Unchanged	8.7 Employees (FTE) 2025: 8.7 ▲ 0.9 vs 2024 (7.8) Unchanged	▲ 0.9

Key figures of BELDIMED, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to BELDIMED?

What happened at BELDIMED in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 17, 2026 New annual accounts for financial year 2025: profit of € 38,202 (▼ 76% vs 2024). Source: NBB ↗
Mar 4, 1994 New establishment in Dison. KBO
Feb 8, 1994 Start of the company according to the CBE. KBO

In short

From € 72,511 profit in 2022 to € 38,202 profit in 2025.

Paid € 117,572 in corporate taxes since 2022.

Best year ever: 2024, with € 157,019 profit.

On average € 90,700 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

EAGLE FINANCE 100%

The stake of EAGLE FINANCE comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

BELDIMED

IKRIS PHARMA INTERNATIONAL 50%

Behind BELDIMED is Eagle Finance. The shares are held by EAGLE FINANCE (100%). It owns 50% of IKRIS PHARMA INTERNATIONAL itself.

Directors

According to the 2025 annual accounts

Eagle Finance

Director · represented by Philipp Gertrude Quodbach

Shareholders

EAGLE FINANCE

100%

Participations

IKRIS PHARMA INTERNATIONAL

50%

Establishments

Establishment units

Physical locations of this company

Registered office

Rue Zénobe Gramme 39

4821 Dison

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 6 companies are registered at this address.

All companies at this address →

POP N PLAY

IKRIS PHARMA INTERNATIONAL same network

€ -7,103 gross margin · 2025

FAMILIA

€ 255,041 gross margin · 2025

OLSEN ENGINEERING

€ 3.5 million gross margin · 2025

Link Office

€ 2,624 gross margin · 2024

+1 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Website

HTTPS beldimed.com

About

Technologies

AddToAnyApacheComplianzContact Form 7ElementorFont AwesomeGoogle AnalyticsPHPSwiperWPMLWordPressYoast SEOYouTube EmbedjQueryjQuery UIlazysizesreCAPTCHAunpkg

Hosting & Email

Email provider

Self-hosted

Hosting

VERIXI, BE

Domain

beldimed.com

Registered

2017-04-09

Registrar

Hosting Concepts B.V. d/b/a Registrar.eu

Expires

2027-04-09

Website info

HTTPS Ja

Languages EN

Features

Contact page

Security

✓ HTTPS

✓ SPF

✓ DMARC

Details

Company number

0451.903.697

VAT number

BE 0451.903.697

Registered office

Rue Zénobe Gramme 39, 4821 Dison

Names & denominations

BELDIMED

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

8 February 1994

Peppol

Active · Active since 20 Nov 2020

Contact

beldimed.com

Activities · NACE

Groothandel in farmaceutische producten

Groothandel in farmaceutische en medische artikelen

Handelsbemiddeling in de groothandel in andere specifieke goederen

Handelsbemiddeling gespecialiseerd in overige goederen, n.e.g.

View on CBE Public ↗ Annual accounts (NBB) ↗

BELDIMED

Financials

What happened to BELDIMED?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Website

Technologies

Hosting & Email

Domain

Website info

Features

Security

Details

Frequently asked questions